• Je něco špatně v tomto záznamu ?

Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner

K. Valis, L. Prochazka, E. Boura, J. Chladova, T. Obsil, J. Rohlena, J. Truksa, LF. Dong, SJ. Ralph, J. Neuzil

. 2011 ; 71 (3) : 946-954. [pub] 20110118

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027113

The proapoptotic protein Noxa, a member of the BH3-only Bcl-2 protein family, can effectively induce apoptosis in cancer cells, although the relevant regulatory pathways have been obscure. Previous studies of the cytotoxic effects of α-tocopheryl succinate (α-TOS) on cancer cells identified a mechanism whereby α-TOS caused apoptosis requiring the Noxa-Bak axis. In the present study, ab initio analysis revealed a conserved FoxO-binding site (DBE; DAF-16 binding element) in the NOXA promoter, and specific affinity of FoxO proteins to this DBE was confirmed by fluorescence anisotropy. FoxO1 and FoxO3a proteins accumulated in the nucleus of α-TOS-treated cells, and the drug-induced specific FoxO1 association with the NOXA promoter and its activation were validated by chromatin immunoprecipitation. Using siRNA knockdown, a specific role for the FoxO1 protein in activating NOXA transcription in cancer cells was identified. Furthermore, the proapoptotic kinase Hippo/Mst1 was found to be strongly activated by α-TOS, and inhibiting Hippo/Mst1 by specific siRNA prevented phosphorylation of FoxO1 and its nuclear translocation, thereby reducing levels of NOXA transcription and apoptosis in cancer cells exposed to α-TOS. Thus, we have demonstrated that anticancer drugs, exemplified by α-TOS, induce apoptosis by a mechanism involving the Hippo/Mst1-FoxO1-Noxa pathway. We propose that activation of this pathway provides a new paradigm for developing targeted cancer treatments.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027113
003      
CZ-PrNML
005      
20160417111420.0
007      
ta
008      
120816s2011 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1158/0008-5472.can-10-2203 $2 doi
035    __
$a (PubMed)21245099
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vališ, Karel. $7 _AN058828 $u Molecular Therapy Group, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Karel.Valis@img.cas.cz
245    10
$a Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner / $c K. Valis, L. Prochazka, E. Boura, J. Chladova, T. Obsil, J. Rohlena, J. Truksa, LF. Dong, SJ. Ralph, J. Neuzil
520    9_
$a The proapoptotic protein Noxa, a member of the BH3-only Bcl-2 protein family, can effectively induce apoptosis in cancer cells, although the relevant regulatory pathways have been obscure. Previous studies of the cytotoxic effects of α-tocopheryl succinate (α-TOS) on cancer cells identified a mechanism whereby α-TOS caused apoptosis requiring the Noxa-Bak axis. In the present study, ab initio analysis revealed a conserved FoxO-binding site (DBE; DAF-16 binding element) in the NOXA promoter, and specific affinity of FoxO proteins to this DBE was confirmed by fluorescence anisotropy. FoxO1 and FoxO3a proteins accumulated in the nucleus of α-TOS-treated cells, and the drug-induced specific FoxO1 association with the NOXA promoter and its activation were validated by chromatin immunoprecipitation. Using siRNA knockdown, a specific role for the FoxO1 protein in activating NOXA transcription in cancer cells was identified. Furthermore, the proapoptotic kinase Hippo/Mst1 was found to be strongly activated by α-TOS, and inhibiting Hippo/Mst1 by specific siRNA prevented phosphorylation of FoxO1 and its nuclear translocation, thereby reducing levels of NOXA transcription and apoptosis in cancer cells exposed to α-TOS. Thus, we have demonstrated that anticancer drugs, exemplified by α-TOS, induce apoptosis by a mechanism involving the Hippo/Mst1-FoxO1-Noxa pathway. We propose that activation of this pathway provides a new paradigm for developing targeted cancer treatments.
650    _2
$a apoptóza $x fyziologie $7 D017209
650    _2
$a nemalobuněčný karcinom plic $x genetika $x metabolismus $x patologie $x terapie $7 D002289
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a forkhead transkripční faktory $x genetika $x metabolismus $7 D051858
650    _2
$a lidé $7 D006801
650    _2
$a Jurkat buňky $7 D019169
650    _2
$a nádory plic $x genetika $x metabolismus $x patologie $x terapie $7 D008175
650    _2
$a lymfom T-buněčný $x genetika $x metabolismus $x patologie $x terapie $7 D016399
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a protein-serin-threoninkinasy $x antagonisté a inhibitory $x genetika $x metabolismus $7 D017346
650    _2
$a protoonkogenní proteiny c-bcl-2 $x biosyntéza $x genetika $x metabolismus $7 D019253
650    _2
$a malá interferující RNA $x aplikace a dávkování $x genetika $7 D034741
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a signální transdukce $7 D015398
650    _2
$a genetická transkripce $7 D014158
650    _2
$a alfa-tokoferol $x farmakologie $7 D024502
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Procházka, Lubomír $7 xx0100254 $u Veterinary Research Institute, Brno, Czech Republic; and 5School of Medical Science, Griffith University, Southport, Queensland, Australia
700    1#
$a Bouřa, Evžen. $7 xx0119184 $u Protein Structure Group, Institute of Physiology, Academy of Sciences of the Czech Republic
700    1_
$a Chladova, Jaromira $u Molecular Therapy Group, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Obšil, Tomáš, $d 1972- $7 uk2007304264 $u Protein Structure Group, Institute of Physiology, Academy of Sciences of the Czech Republic; Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Rohlena, Jakub $7 xx0166966 $u Molecular Therapy Group, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Truksa, Jaroslav $7 xx0128857 $u Molecular Therapy Group, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Dong, Lan-Feng $u Apoptosis Research Group, School of Medical Science and the Griffith Health Institute, Griffith University, Southport, 4222, Queensland, Australia
700    1_
$a Ralph, Stephen J $u Apoptosis Research Group, School of Medical Science and the Griffith Health Institute, Griffith University, Southport, 4222, Queensland, Australia
700    1_
$a Neužil, Jiří, $d 1958- $7 xx0115772 $u Molecular Therapy Group, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Apoptosis Research Group, School of Medical Science and the Griffith Health Institute, Griffith University, Southport, 4222, Queensland, Australia
773    0_
$w MED00009437 $t Cancer research $x 1538-7445 $g Roč. 71, č. 3 (2011), s. 946-954
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21245099 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20160417111507 $b ABA008
999    __
$a ok $b bmc $g 949155 $s 784459
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 71 $c 3 $d 946-954 $e 20110118 $i 1538-7445 $m Cancer research $n Cancer Res $x MED00009437
LZP    __
$b NLK122 $a Pubmed-20120816/11/02

Najít záznam

Citační ukazatele

Možnosti archivace